News & Events

Biosion, Inc. Licenses BSI04702, An Anti-TROP-2 mAb, to OBI Pharma, Inc. for Worldwide Development and Commercialization Rights as an Antibody Drug Conjugate and Other Derivative Products

December 13, 2021

This license agreement continues to build on Biosion s efforts to create and develop meaningful biologics to treat resistant relapsed and residual disease for patients worldwide Newark DE USA Nanjing China December Biosion Inc Biosion a global clinical stage biotech company announced today that [...]

LEARN MORE

Biosion, Inc. Completed Pre-B+ Round Financing to Accelerate the Discovery and Global Development of Its Innovative Biologics Pipeline

December 9, 2021

New funding will strengthen Biosion s In Global For Global positioning by accelerating its clinical pipeline and expanding its global biologics development teams Newark DE Nanjing CN Dec Biosion Inc Biosion a global clinical-stage biotech company today announced completion of a million RMB preB [...]

LEARN MORE

Biosion, Inc. and Celldex present positive preclinical data at SITC 2021. CDX-585 is the first compound from Celldex’s research and collaboration agreement with Biosion, Inc. and combines Celldex’s ILT4 mAb with Biosion’s PD-1 mAb.

November 12, 2021

Celldex Presents Positive Preclinical Data from PD- ILT Bispecific Antibody Program CDX- at SITC HAMPTON N J November -- Celldex Therapeutics Inc today announced positive preclinical data from CDX- the Company s bispecific antibody with dual targeting of ILT and PD- checkpoint pathways developed [...]

LEARN MORE

Biosion, Inc. Appoints Yao-Yao Zhu, M.D., Ph.D., Head of Global Regulatory Affairs

October 18, 2021

NEWARK Delaware and NANJING China September Biosion Inc announced the appointment of Dr Yao-Yao Zhu as Head of Global Regulatory Affairs Dr Zhu joins Biosion from U S FDA where she served as Medical Officer in the Office of Immunology and Inflammation Office of [...]

LEARN MORE
Close Bitnami banner
Bitnami